
From left front row: Kaho Kamihira and Sayuri Otsubo; Back row: Kiko Kawamura, Kanako Hironai and Ruriko Sotoyama
13:25 JST, May 29, 2024
MORIOKA — Dancers for this year’s “Miss Sansa Odori” have been decided. The final judging of the five who will lead the Morioka Sansa Odori Festival parade was held at Plaza Odette in Morioka on May 11.
Applicants for the position must be women who are single and between the ages of 18 and 28. They must live in Morioka or neighboring cities and towns. This year, there were 64 applicants — 16 more than last year — and the 12 who passed the preliminary screening went on to the final judging that was open to the public.
The five dancers are Iwate University student Kaho Kamihira, 20; association worker Sayuri Otsubo, 23; company employees Kiko Kawamura, 24, and Kanako Hironai, 25; and Iwate Medical University sixth-year student Ruriko Sotoyama, 23.
“It was a complete surprise and honestly I am happy,” said Kamihira, who has never danced Sansa before. “I want to do my best so that all five of us can dance together in harmony.”
They will begin practicing in June in preparation for their debut performance at the end of July at an event at Morioka’s Mitsuishi Shrine. After the festival in August, they will continue to promote Morioka and Iwate tourism in Japan and abroad.
Related Tags
Top Articles in Features
-
Japanese Students Use Traditional Pickle to Create Novel Wagashi Confectionery
-
My Spendthrift Mother Constantly Asks Me for Money
-
Kawazu Cherry Blossoms in Full Bloom in Japan’s Shizuoka Pref.; Festival to Be Held through March 8
-
Tourists Ignore Safety Barriers Near Famous Zao ‘Snow Monsters’ in Japan
-
Tottori: 95-Year-Old Japanese Descendent from Philippines Visits Father’s Grave
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

